Literature DB >> 31945495

Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.

Tiphaine Delaunay1, Carole Achard1, Nicolas Boisgerault1, Marion Grard1, Tacien Petithomme1, Camille Chatelain1, Soizic Dutoit1, Christophe Blanquart1, Pierre-Joseph Royer2, Stéphane Minvielle3, Lisa Quetel4, Clément Meiller4, Didier Jean4, Delphine Fradin1, Jaafar Bennouna5, Antoine Magnan6, Laurent Cellerin7, Frédéric Tangy8, Marc Grégoire1, Jean-François Fonteneau9.   

Abstract

INTRODUCTION: Oncolytic immunotherapy is based on the use of nonpathogenic replicative oncolytic viruses that infect and kill tumor cells exclusively. Recently, we found that the spontaneous oncolytic activity of the Schwarz strain of measles virus (MV) against human malignant pleural mesothelioma (MPM) depends on defects in the antiviral type I interferon (IFN-I) response in tumor cells.
METHODS: In this study, we studied three independent human MPM bio-collections to identify the defects in the IFN-I responses in tumor cells.
RESULTS: We show that the most frequent defect is the homozygous deletions (HDs) of all the 14 IFN-I genes (IFN-α and IFN-β) that we found in more than half of MV-sensitive MPM cell lines. These HDs occur together with the HDs of the tumor suppressor gene CDKN2A also located in the 9p21.3 chromosome region. Therefore, the IFN-I-/- MPM cell lines develop a partial and weak IFN-I response when they are exposed to the virus compared with that of normal cells and MV-resistant MPM cell lines. This response consists of the expression of a restricted number of IFN-stimulated genes that do not depend on the presence of IFN-I. In addition, the IFN-I-/- MPM cell lines infected by MV also develop a pro-inflammatory response associated with stress of the endoplasmic reticulum.
CONCLUSION: Our study emphasizes the link between HDs of IFN-I encoding genes and the CDKN2A gene in MPM and sensitivity to MV oncolytic immunotherapy.
Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Gene homozygous deletion; Measles virus; Mesothelioma; Oncolytic immunotherapy; Type I interferon

Mesh:

Substances:

Year:  2020        PMID: 31945495     DOI: 10.1016/j.jtho.2019.12.128

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  14 in total

Review 1.  Delivery of cancer therapies by synthetic and bio-inspired nanovectors.

Authors:  Tina Briolay; Tacien Petithomme; Morgane Fouet; Nelly Nguyen-Pham; Christophe Blanquart; Nicolas Boisgerault
Journal:  Mol Cancer       Date:  2021-03-24       Impact factor: 27.401

Review 2.  Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.

Authors:  Steven G Gray
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

Review 3.  Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements.

Authors:  Ke-Tao Jin; Wen-Lin Du; Yu-Yao Liu; Huan-Rong Lan; Jing-Xing Si; Xiao-Zhou Mou
Journal:  Cancers (Basel)       Date:  2021-02-03       Impact factor: 6.639

Review 4.  24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".

Authors:  Noémie Joalland; Kathleen Ducoin; Gwenann Cadiou; Catherine Rabu; Carole Guillonneau
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 5.  Oncolytic Virotherapy: From Bench to Bedside.

Authors:  Ludi Yang; Xiang Gu; Jie Yu; Shengfang Ge; Xianqun Fan
Journal:  Front Cell Dev Biol       Date:  2021-11-26

6.  KRAS signaling in malignant pleural mesothelioma.

Authors:  Antonia Marazioti; Anthi C Krontira; Sabine J Behrend; Georgia A Giotopoulou; Giannoula Ntaliarda; Anne-Sophie Lamort; Georgios T Stathopoulos; Christophe Blanquart; Hasan Bayram; Marianthi Iliopoulou; Malamati Vreka; Lilith Trassl; Mario A A Pepe; Caroline M Hackl; Laura V Klotz; Stefanie A I Weiss; Ina Koch; Michael Lindner; Rudolph A Hatz; Juergen Behr; Darcy E Wagner; Helen Papadaki; Sophia G Antimisiaris; Didier Jean; Sophie Deshayes; Marc Grégoire; Özgecan Kayalar; Deniz Mortazavi; Şükrü Dilege; Serhan Tanju; Suat Erus; Ömer Yavuz; Pınar Bulutay; Pınar Fırat; Ioannis Psallidas; Magda Spella; Ioanna Giopanou; Ioannis Lilis
Journal:  EMBO Mol Med       Date:  2021-12-13       Impact factor: 12.137

Review 7.  Apoptosis during ZIKA Virus Infection: Too Soon or Too Late?

Authors:  Jonathan Turpin; Daed El Safadi; Grégorie Lebeau; Morgane Krejbich; Camille Chatelain; Philippe Desprès; Wildriss Viranaïcken; Pascale Krejbich-Trotot
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

Review 8.  Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.

Authors:  Benjamin Wadowski; Raphael Bueno; Assunta De Rienzo
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

Review 9.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy.

Authors:  Marion Grard; Camille Chatelain; Tiphaine Delaunay; Elvire Pons-Tostivint; Jaafar Bennouna; Jean-François Fonteneau
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  Integrated genomics point to immune vulnerabilities in pleural mesothelioma.

Authors:  Anca Nastase; Amit Mandal; Shir Kiong Lu; Hima Anbunathan; Deborah Morris-Rosendahl; Yu Zhi Zhang; Xiao-Ming Sun; Spyridon Gennatas; Robert C Rintoul; Matthew Edwards; Alex Bowman; Tatyana Chernova; Tim Benepal; Eric Lim; Anthony Newman Taylor; Andrew G Nicholson; Sanjay Popat; Anne E Willis; Marion MacFarlane; Mark Lathrop; Anne M Bowcock; Miriam F Moffatt; William O C M Cookson
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.